Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Incretin‐based therapies encompass two new classes of antidiabetic drugs: glucagon‐like peptide‐1 (GLP‐l) receptor agonists (e.g., liraglutide, exenatide, and exenatide long‐acting release), which are structurally related to GLP‐l, and the dipeptidyl peptidase‐4 (DPP‐4) inhibitors (e.g., sitagliptin and saxagliptin), which limit the breakdown of endogenous GLP‐l. To evaluate the safety and effectiveness of incretin‐based therapies for the treatment of type 2 diabetes mellitus and the role of these therapies in clinical practice, a MEDLINE search (January 1985‐November 2009) was conducted. Relevant references from the publications identified were also reviewed. Of 28 studies identified, 22 were randomized controlled trials. Data show that these therapies affect insulin secretion in a glucose‐dependent manner, achieving clinically meaningful reductions in hemoglobin A 1c levels, with very low rates of hypoglycemia. In addition, reductions in body weight have been observed with GLP‐l receptor agonists, which also exert a pronounced effect on systolic blood pressure. Various human and animal studies show that GLP‐l improves β‐cell function and increases β‐cell proliferation in vitro, which may slow disease progression. Thus, incretin‐based therapies represent a promising addition to the available treatments for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 2×
“The differing mode of action may play a role in this, since DPP-4 inhibitors do not raise GLP-1 concentrations to the supraphysiologic levels achieved by GLP-1 receptor agonist treatment.(61) In addition, the DPP-4 enzyme acts on peptides other than GLP-1 (including GIP, which is therefore also elevated).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Cited by
Dobrian, A. D., Ma, Q., Lindsay, J. W., Leone, K. A., Ma, K., Coben, J., Galkina, E. V., & Nadler, J. L. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00463.2010 · Cited by 166
Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148
Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125
“The first GLP-1 mimetic, Exenatide (Byetta), reached the market in 2005 closely followed by Liraglutide (Victoza) [11].”
BackgroundKendall, C. W. C., West, S. G., Augustin, L. S., Esfahani, A., Vidgen, E., Bashyam, B., Sauder, K. A., Campbell, J., Chiavaroli, L., Jenkins, A. L., et al. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2013.275 · Cited by 72
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“53%) [113], it is not known whether the findings of Butler and coauthors [88], which did not include liraglutide users, could be applied to users of liraglutide [46].”
Background
Metadata
- Authors
- Drab, S. R.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2010-06
- Volume
- 30
- Issue
- 6
- Pages
- 609-624
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2050938327
- Cited by
- 51
- References
- 47
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.